# MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

> **NCT06543511** · NA · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Myeloid Malignancy
- Myeloid Malignancies
- Blood Cancer
- Blood Cancers

## Interventions

- **OTHER:** Genetic Blood Test

## Key facts

- **NCT ID:** NCT06543511
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-07-29
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Contractual issues. Will be re-submitted as new protocol.
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06543511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06543511, "MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06543511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*